Machine learning identifies factors most associated with seeking medical care for migraine: Results of the OVERCOME (US) study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

  • Ashina, Sait
  • E. Jolanda Muenzel
  • Robert A. Nicholson
  • Anthony J. Zagar
  • Dawn C. Buse
  • Michael L. Reed
  • Robert E. Shapiro
  • Susan Hutchinson
  • Eric M. Pearlman
  • Richard B. Lipton

Objective: Utilize machine learning models to identify factors associated with seeking medical care for migraine. Background: Migraine is a leading cause of disability worldwide, yet many people with migraine do not seek medical care. Methods: The web-based survey, ObserVational survey of the Epidemiology, tReatment and Care Of MigrainE (US), annually recruited demographically representative samples of the US adult population (2018–2020). Respondents with active migraine were identified via a validated diagnostic questionnaire and/or a self-reported medical diagnosis of migraine, and were then asked if they had consulted a healthcare professional for their headaches in the previous 12 months (i.e., “seeking care”). This included in-person/telephone/or e-visit at Primary Care, Specialty Care, or Emergency/Urgent Care locations. Supervised machine learning (Random Forest) and Least Absolute Shrinkage and Selection Operator (LASSO) algorithms identified 13/54 sociodemographic and clinical factors most associated with seeking medical care for migraine. Random Forest models complex relationships (including interactions) between predictor variables and a response. LASSO is also an efficient feature selection algorithm. Linear models were used to determine the multivariable association of those factors with seeking care. Results: Among 61,826 persons with migraine, the mean age was 41.7 years (±14.8) and 31,529/61,826 (51.0%) sought medical care for migraine in the previous 12 months. Of those seeking care for migraine, 23,106/31,529 (73.3%) were female, 21,320/31,529 (67.6%) were White, and 28,030/31,529 (88.9%) had health insurance. Severe interictal burden (assessed via the Migraine Interictal Burden Scale-4, MIBS-4) occurred in 52.8% (16,657/31,529) of those seeking care and in 23.1% (6991/30,297) of those not seeking care; similar patterns were observed for severe migraine-related disability (assessed via the Migraine Disability Assessment Scale, MIDAS) (36.7% [11,561/31,529] vs. 14.6% [4434/30,297]) and severe ictal cutaneous allodynia (assessed via the Allodynia Symptom Checklist, ASC-12) (21.0% [6614/31,529] vs. 7.4% [2230/30,297]). Severe interictal burden (vs. none, OR 2.64, 95% CI [2.5, 2.8]); severe migraine-related disability (vs. little/none, OR 2.2, 95% CI [2.0, 2.3]); and severe ictal allodynia (vs. none, OR 1.7, 95% CI [1.6, 1.8]) were strongly associated with seeking care for migraine. Conclusions: Seeking medical care for migraine is associated with higher interictal burden, disability, and allodynia. These findings could support interventions to promote care-seeking among people with migraine, encourage assessment of these factors during consultation, and prioritize these domains in selecting treatments and measuring their benefits.

OriginalsprogEngelsk
TidsskriftHeadache
Antal sider13
ISSN0017-8748
DOI
StatusE-pub ahead of print - 2024

Bibliografisk note

Funding Information:
This study was funded by Eli Lilly and Company. No other funding was sought.

Funding Information:
provided consulting and teaching services and received honoraria from Allergan/AbbVie, Amgen, Biohaven Pharmaceuticals, Eli Lilly and Company, Impel NeuroPharma, Lundbeck, Novartis, Satsuma, Supernus, Percept, Teva, and Theranica. is an employee and minor stockholder of Eli Lilly and Company. is an employee and minor stockholder of Eli Lilly and Company. is an employee and minor stockholder of Eli Lilly and Company. has received research support from the FDA and the National Headache Foundation. She serves as consultant, advisory board member, or has received honoraria or research support from AbbVie/Allergan, Amgen, Biohaven, Collegium, Eli Lilly and Company, Lundbeck, Novartis, Teva and Theranica. has received research support from the National Headache Foundation. He serves as consultant, advisory board member, or has received honoraria or research support from AbbVie/Allergan, Allay Lamp, Dr. Reddy's Laboratories (Promius), and Eli Lilly and Company. serves as consultant, advisory board member, or has received honoraria or research support from Eli Lilly and Company and Lundbeck. serves as consultant and speaker and has received honoraria from Alder/Lundbeck, AbbVie/Allergan, Amgen, Biohaven, Currax, electroCore, Eli Lilly and Company, Impel, Novartis, Teva, Theranica, and Upsher\u2010Smith. is an employee and minor stockholder of Eli Lilly and Company. has received research support from the National Institutes of Health, the FDA, and the National Headache Foundation. He serves as consultant, advisory board member, or has received honoraria or research support from AbbVie/Allergan, Aeon, Amgen, Biohaven, Dr. Reddy's Laboratories (Promius), electroCore, Eli Lilly and Company, GlaxoSmithKline, Lilly, Lundbeck, Merck, Novartis, Pfizer, Teva, Vector, and Vedanta Research. He receives royalties from Wolff's Headache, 8th edition (Oxford University Press, 2009) and Informa. He holds stock/options in Axon, Biohaven, CoolTech, and Mainistee. Sait Ashina E. Jolanda Muenzel Robert A. Nicholson Anthony J. Zagar Dawn C. Buse Michael L. Reed Robert E. Shapiro Susan Hutchinson Eric M. Pearlman Richard B. Lipton

Publisher Copyright:
© 2024 Eli Lilly and Company and The Author(s). Headache: The Journal of Head and Face Pain published by Wiley Periodicals LLC on behalf of American Headache Society.

ID: 393464810